Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 26.22
XON's Cash to Debt is ranked lower than
53% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. XON: 26.22 )
Ranked among companies with meaningful Cash to Debt only.
XON' s Cash to Debt Range Over the Past 10 Years
Min: 9.17  Med: 107.37 Max: 118.37
Current: 26.22
9.17
118.37
Equity to Asset 0.71
XON's Equity to Asset is ranked higher than
52% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. XON: 0.71 )
Ranked among companies with meaningful Equity to Asset only.
XON' s Equity to Asset Range Over the Past 10 Years
Min: -2.12  Med: 0.67 Max: 0.78
Current: 0.71
-2.12
0.78
F-Score: 6
Z-Score: 5.81
M-Score: -2.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -84.60
XON's Operating margin (%) is ranked lower than
52% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. XON: -84.60 )
Ranked among companies with meaningful Operating margin (%) only.
XON' s Operating margin (%) Range Over the Past 10 Years
Min: -1028.67  Med: -244.20 Max: -84.6
Current: -84.6
-1028.67
-84.6
Net-margin (%) -48.67
XON's Net-margin (%) is ranked higher than
53% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. XON: -48.67 )
Ranked among companies with meaningful Net-margin (%) only.
XON' s Net-margin (%) Range Over the Past 10 Years
Min: -1064.27  Med: -164.06 Max: -48.67
Current: -48.67
-1064.27
-48.67
ROE (%) -14.50
XON's ROE (%) is ranked higher than
63% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. XON: -14.50 )
Ranked among companies with meaningful ROE (%) only.
XON' s ROE (%) Range Over the Past 10 Years
Min: -254.03  Med: -21.78 Max: -15.66
Current: -14.5
-254.03
-15.66
ROA (%) -10.15
XON's ROA (%) is ranked higher than
65% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. XON: -10.15 )
Ranked among companies with meaningful ROA (%) only.
XON' s ROA (%) Range Over the Past 10 Years
Min: -61.45  Med: -14.10 Max: -10.84
Current: -10.15
-61.45
-10.84
ROC (Joel Greenblatt) (%) -132.97
XON's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. XON: -132.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
XON' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -438.75  Med: -235.39 Max: -160.11
Current: -132.97
-438.75
-160.11
» XON's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

XON Guru Trades in Q1 2015

Chase Coleman 300,000 sh (New)
T Boone Pickens 17,500 sh (+75.00%)
First Eagle Investment 828,104 sh (+4.84%)
Daniel Loeb 2,700,000 sh (-6.90%)
» More
Q2 2015

XON Guru Trades in Q2 2015

First Eagle Investment 872,604 sh (+5.37%)
Daniel Loeb 2,700,000 sh (unchged)
T Boone Pickens 17,500 sh (unchged)
Chase Coleman Sold Out
» More
Q3 2015

XON Guru Trades in Q3 2015

First Eagle Investment 1,009,689 sh (+15.71%)
T Boone Pickens Sold Out
Daniel Loeb 1,500,000 sh (-44.44%)
» More
Q4 2015

XON Guru Trades in Q4 2015

Joel Greenblatt 57,418 sh (New)
Chase Coleman 1,675,000 sh (New)
First Eagle Investment 1,187,389 sh (+17.60%)
Daniel Loeb Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with XON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Intrexon Corp

CEO and Part Owner of JMP Group Invests in Company Joseph Jolson acquires 87,532 company shares
Joseph Jolson (Insider Trades), CEO and 10% owner of JMP Group LLC (JMP), bought 87,532 shares in the company on Jan. 19. Read more...

Ratios

vs
industry
vs
history
P/B 4.41
XON's P/B is ranked lower than
62% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. XON: 4.41 )
Ranked among companies with meaningful P/B only.
XON' s P/B Range Over the Past 10 Years
Min: 3.61  Med: 6.05 Max: 15.08
Current: 4.41
3.61
15.08
P/S 16.69
XON's P/S is ranked lower than
59% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. XON: 16.69 )
Ranked among companies with meaningful P/S only.
XON' s P/S Range Over the Past 10 Years
Min: 5.92  Med: 25.06 Max: 55.59
Current: 16.69
5.92
55.59
PFCF 134.67
XON's PFCF is ranked lower than
90% of the 116 Companies
in the Global Biotechnology industry.

( Industry Median: 30.80 vs. XON: 134.67 )
Ranked among companies with meaningful PFCF only.
XON' s PFCF Range Over the Past 10 Years
Min: 131.64  Med: 184.39 Max: 7130
Current: 134.67
131.64
7130
POCF 84.71
XON's POCF is ranked lower than
87% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. XON: 84.71 )
Ranked among companies with meaningful POCF only.
XON' s POCF Range Over the Past 10 Years
Min: 82.81  Med: 115.99 Max: 462.13
Current: 84.71
82.81
462.13
EV-to-EBIT -33.22
XON's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. XON: -33.22 )
Ranked among companies with meaningful EV-to-EBIT only.
XON' s EV-to-EBIT Range Over the Past 10 Years
Min: -3250.6  Med: -42.15 Max: -13.2
Current: -33.22
-3250.6
-13.2
EV-to-EBITDA -41.89
XON's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. XON: -41.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
XON' s EV-to-EBITDA Range Over the Past 10 Years
Min: -284.7  Med: -44.30 Max: 424.7
Current: -41.89
-284.7
424.7
Current Ratio 4.27
XON's Current Ratio is ranked lower than
54% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. XON: 4.27 )
Ranked among companies with meaningful Current Ratio only.
XON' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.68 Max: 9.46
Current: 4.27
0.81
9.46
Quick Ratio 3.92
XON's Quick Ratio is ranked lower than
54% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. XON: 3.92 )
Ranked among companies with meaningful Quick Ratio only.
XON' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.14 Max: 9.46
Current: 3.92
0.81
9.46
Days Inventory 146.00
XON's Days Inventory is ranked lower than
58% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. XON: 146.00 )
Ranked among companies with meaningful Days Inventory only.
XON' s Days Inventory Range Over the Past 10 Years
Min: 149.45  Med: 196.91 Max: 244.37
Current: 146
149.45
244.37
Days Sales Outstanding 52.77
XON's Days Sales Outstanding is ranked higher than
60% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. XON: 52.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
XON' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.91  Med: 12.14 Max: 73.99
Current: 52.77
0.91
73.99
Days Payable 28.36
XON's Days Payable is ranked lower than
73% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. XON: 28.36 )
Ranked among companies with meaningful Days Payable only.
XON' s Days Payable Range Over the Past 10 Years
Min: 28.36  Med: 73.57 Max: 118.77
Current: 28.36
28.36
118.77

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 84.71
XON's Price/Net Current Asset Value is ranked lower than
97% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. XON: 84.71 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
XON' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 26.38  Med: 61.82 Max: 97.26
Current: 84.71
26.38
97.26
Price/Tangible Book 10.89
XON's Price/Tangible Book is ranked lower than
79% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. XON: 10.89 )
Ranked among companies with meaningful Price/Tangible Book only.
XON' s Price/Tangible Book Range Over the Past 10 Years
Min: 7.16  Med: 12.26 Max: 12.5
Current: 10.89
7.16
12.5
Price/Median PS Value 0.66
XON's Price/Median PS Value is ranked higher than
72% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. XON: 0.66 )
Ranked among companies with meaningful Price/Median PS Value only.
XON' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 0.76 Max: 1.46
Current: 0.66
0.43
1.46
Earnings Yield (Greenblatt) (%) -3.00
XON's Earnings Yield (Greenblatt) (%) is ranked higher than
62% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. XON: -3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
XON' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.6  Med: 0.00 Max: 0
Current: -3
-3.6
0

More Statistics

Revenue(Mil) $174
EPS $ -0.74
Short Percentage of Float32.95%
52-Week Range $18.52 - 69.45
Shares Outstanding(Mil)116.78

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:GILD, NAS:AMGN, NAS:CELG, NAS:BIIB » details
Traded in other countries:I5X.Germany,
Intrexon Corp was founded in 1998. The Company designs, builds and regulates gene programs and cellular systems to enable the development of new and improved products and processes across a variety of market sectors, including Health, Food, Energy and Environment.The Company operates in one segment. It uses synthetic biology for the creation of distinct products developed in collaboration with partners. All of the Company's revenues are derived in the United States of America and all of its assets are located in the United States of America. The Company is subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials and the health and safety of employees with respect to laboratory activities required for the development of products and technologies.
» More Articles for XON

Headlines

Articles On GuruFocus.com
CEO and Part Owner of JMP Group Invests in Company Jan 20 2016 
Intrexon Corp is expanding his business Jun 25 2015 
Bill Miller Identifies What Could Be The Stock of The Decade Feb 10 2015 
5-Year Lows: American Eagle Outfitters, Intrexon Corp, Mack-Cali Realty Corp, and Weight Watchers In Apr 20 2014 
Daniel Loeb Comments on Intrexon Corporation Jan 22 2014 
Daniel Loeb Lags S&P But Top New Stocks Advance Jan 07 2014 
David Einhorn’s New Stocks – TPX, XON, NVR Nov 14 2013 
Weekly CEO Buys Highlight: XON, ARCP, FSFR, CNTY, RHP Aug 18 2013 

More From Other Websites
INTREXON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... May 03 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intrexon... May 03 2016
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intrexon Corporation of Class... May 03 2016
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Intrexon Corporation -... May 03 2016
Coverage initiated on Intrexon by JMP Securities May 03 2016
Intrexon to Announce First Quarter 2016 Financial Results on May 10th Apr 28 2016
Intrexon to Announce First Quarter 2016 Financial Results on May 10th Apr 28 2016
Intrexon Brushes Off Latest Critical Report Apr 27 2016
Qiwi, Robert Half, Celator Pharma, Encana, and ArcelorMittal All Take Tumbles on Wednesday Apr 27 2016
Why Traders Are Selling These Five Tanking Stocks? Apr 27 2016
Here's Why Intrexon (XON) Stock Is Plummeting Today Apr 27 2016
INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Intrexon Corporation... Apr 27 2016
Game-Changing Animal Research Models Offer Superior Translational Research and Better Predictive... Apr 27 2016
Wolf Popper LLP Announces Investigation of Fraud Claims on Behalf of Investors in Intrexon... Apr 26 2016
ETF’s with exposure to Intrexon Corp. : April 25, 2016 Apr 25 2016
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intrexon... Apr 25 2016
Intrexon Bruised by Blind Short-Seller Report Apr 25 2016
Your dream of a world without mosquitoes is one step closer to coming true Apr 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK